Answers are grounded in this paper and cite their sources.
A single dose of the mRNA-1345 vaccine resulted in no evident safety concerns and led to a lower incidence of RSV-associated lower respiratory tract disease and of RSV-associated acute respiratory disease than placebo among adults 60 years of age or older. (Funded by Moderna; ConquerRSV ClinicalTrials.gov number, NCT05127434.).
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: